Translating Immunotherapy Innovation Program

This program demonstrates a translational model where a new company forms to take immunotherapy-based innovations to market, and includes translational research undertaken by the founding CEO of TRI, Professor Ian Frazer. 

What are immunotherapies?

Immunotherapies are a type of 'biological therapy' that influence the immune system and help fight disease. They can work by stimulating the immune system to help your body to identify and target cancer cells, or in other cases may be used to suppress the immune system when it is over-active, such as for treatment of autoimmune disease. These therapies may be in the form of antibodies or vaccines, and can be highly effective for treating various diseases. 

Translating innovations into immunotherapies - to improve treatment options for patients

After a promising discovery is made in the lab, particular expertise and commercial knowledge is required to support further development, so the product can be taken 'to market'. To facilitate this process, forming a company, or partnering with an existing commercial company, can help 'translate' or move these discoveries into the clinic, where they can make a difference for patients. Harnessing learnings from these experiences, we can use this knowledge to inform our approach to take further innovations to market, and improve health outcomes for patients across other disease areas.